BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 2497974)

  • 21. Induction of c-fos and c-myc expression during B cell activation by IL-4 and immunoglobulin binding ligands.
    Klemsz MJ; Justement LB; Palmer E; Cambier JC
    J Immunol; 1989 Aug; 143(3):1032-9. PubMed ID: 2787345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. c-MYC impairs immunogenicity of human B cells.
    Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
    Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conditioned tumorigenicity of activated oncogenes.
    Klein G; Klein E
    Cancer Res; 1986 Jul; 46(7):3211-24. PubMed ID: 3011242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclic AMP-mediated suppression of normal and neoplastic B cell proliferation is associated with regulation of myc and Ha-ras protooncogenes.
    Blomhoff HK; Smeland EB; Beiske K; Blomhoff R; Ruud E; Bjøro T; Pfeifer-Ohlsson S; Watt R; Funderud S; Godal T
    J Cell Physiol; 1987 Jun; 131(3):426-33. PubMed ID: 3036888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunoglobulin heavy chain variable gene utilization in human large cell and Burkitt's lymphoma cell lines.
    Daley MD; Berinstein NL; Siminovitch KA
    Clin Invest Med; 1994 Dec; 17(6):522-30. PubMed ID: 7895416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B-cell maturation stages of Burkitt's lymphoma cell lines according to Epstein-Barr virus status and type of chromosome translocation.
    Cohen JH; Revillard JP; Magaud JP; Lenoir G; Vuillaume M; Manel AM; Vincent C; Bryon PA
    J Natl Cancer Inst; 1987 Feb; 78(2):235-42. PubMed ID: 3027441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of transforming growth factor-beta 1 induced apoptosis in normal human B cells and lymphoma B cell lines.
    Chaouchi N; Arvanitakis L; Auffredou MT; Blanchard DA; Vazquez A; Sharma S
    Oncogene; 1995 Oct; 11(8):1615-22. PubMed ID: 7478586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
    Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
    Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-B-cell leukemia with a t(8; 14) and a t(14; 18) translocation is preceded by follicular lymphoma.
    Gauwerky CE; Hoxie J; Nowell PC; Croce CM
    Oncogene; 1988 May; 2(5):431-5. PubMed ID: 3131717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Burkitt's lymphomas express VH genes with a moderate number of antigen-selected somatic mutations.
    Tamaru J; Hummel M; Marafioti T; Kalvelage B; Leoncini L; Minacci C; Tosi P; Wright D; Stein H
    Am J Pathol; 1995 Nov; 147(5):1398-407. PubMed ID: 7485402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between the rearrangement of immunoglobulin genes, the appearance of a B lymphocyte antigen, and immunoglobulin synthesis in murine pre-B cell lines.
    Sugiyama H; Akira S; Yoshida N; Kishimoto S; Yamamura Y; Kincade P; Honjo T; Kishimoto T
    J Immunol; 1982 Jun; 128(6):2793-7. PubMed ID: 6281337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Forward and reverse changes in Ig/myc translocation carrying tumors.
    Klein G
    Princess Takamatsu Symp; 1989; 20():135-42. PubMed ID: 2562178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.
    Mathas S; Rickers A; Bommert K; Dörken B; Mapara MY
    Cancer Res; 2000 Dec; 60(24):7170-6. PubMed ID: 11156427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Molecular analysis in Argentinian patients with Burkitt's lymphoma].
    Gutiérrez MI; Barriga F; Díez B; Larripa I; Magrath I
    Sangre (Barc); 1990 Feb; 35(1):10-4. PubMed ID: 2159189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apoptosis in Burkitt lymphoma cells is driven by c-myc.
    Milner AE; Grand RJ; Waters CM; Gregory CD
    Oncogene; 1993 Dec; 8(12):3385-91. PubMed ID: 8247541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
    Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
    Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined polymerase chain reaction methods to detect c-myc/IgH rearrangement in childhood Burkitt's lymphoma for minimal residual disease analysis.
    Busch K; Borkhardt A; Wössmann W; Reiter A; Harbott J
    Haematologica; 2004 Jul; 89(7):818-25. PubMed ID: 15257933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant immunoglobulin and c-myc gene rearrangements in patients with nonmalignant monoclonal cryoglobulinemia.
    Perl A; Wang N; Williams JM; Hunt MJ; Rosenfeld SI; Condemi JJ; Packman CH; Abraham GN
    J Immunol; 1987 Nov; 139(10):3512-20. PubMed ID: 3316385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B lymphoblastoid cell lines with rearranged T cell receptor beta-chain genes retain conventional B cell surface antigen and Ig expression.
    Robinson MA; Kindt TJ
    J Immunol; 1988 Feb; 140(4):1327-34. PubMed ID: 2830338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in c-myc and c-fos expression in a human tumor cell line following exposure to bifunctional alkylating agents.
    Futscher BW; Erickson LC
    Cancer Res; 1990 Jan; 50(1):62-6. PubMed ID: 2104539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.